title: Vitreous and aqueous penetration of intravitreally and orally administered moxifloxacin in an experimental rabbit model of fungal endophthalmitis.
abstract: OBJECTIVE
  Moxifloxacin (MXF), is a fluoroquinolone drug thought to have some antifungal activity against Candida albicans. The aim of our study was to investigate whether intravitreally and orally administered MXF has an effective penetration into the aqueous and vitreous in an experimental model of C. albicans endophthalmitis.
  
  
  METHODS
  Thirty-two New Zealand rabbits were included. Endophthalmitis was induced in the right eyes of the rabbits. Left eyes were used as sham controls. Group 1 received a single dose of 160 μg MXF/0.1 ml intravitreally. Group 2 received a single intravitreal dose of 160 μg MXF/0.1 ml and an oral dose of 7 mg/kg/day for 4 days. Group 3 received only an oral dose of MXF 7 mg/kg/day for 4 days. Group 4 comprised of healthy controls. On the first and fourth day of treatment aqueous and vitreous samples were aspirated to compare the penetration of MXF.
  
  
  RESULTS
  Between the first and fourth days, in group 1, mean MXF levels in the aqueous and vitreous tended to decrease; however, in group 3, these drug levels were tended to increase. There was also a decline in the drug levels in the aqueous and vitreous of group 2.
  
  
  CONCLUSIONS
  MXF cannot achieve sufficient penetration into the aqueous and vitreous of eyes infected with C. albicans.
authors.affiliation: Department of Ophthalmology, Aksaray State Hospital, Aksaray, Turkey.
authors.forename: Sedat
authors.initials: S
authors.lastname: Arikan
authors.forename: Sengul
authors.initials: S
authors.lastname: Ozdek
authors.forename: Zeynep
authors.initials: Z
authors.lastname: Aktas
authors.forename: Aysun
authors.initials: A
authors.lastname: Dinçel
authors.forename: Berati
authors.initials: B
authors.lastname: Hasanreisoglu
mesh_terms: D000818:Animals; D000935:Antifungal Agents / Q000008:administration & dosage / Q000378:metabolism* / Q000627:therapeutic use; D001082:Aqueous Humor / Q000378:metabolism*; D001372:Aza Compounds / Q000008:administration & dosage / Q000378:metabolism* / Q000627:therapeutic use; D002176:Candida albicans; D004195:Disease Models, Animal; D009877:Endophthalmitis / Q000188:drug therapy* / Q000382:microbiology; D015821:Eye Infections, Fungal / Q000188:drug therapy* / Q000382:microbiology; D024841:Fluoroquinolones; D000077266:Moxifloxacin; D011804:Quinolines / Q000008:administration & dosage / Q000378:metabolism* / Q000627:therapeutic use; D011817:Rabbits; D014822:Vitreous Body / Q000378:metabolism*
chemical_list: D000935:Antifungal Agents; D001372:Aza Compounds; D024841:Fluoroquinolones; D011804:Quinolines; D000077266:Moxifloxacin